Azitra Future Growth

Future criteria checks 2/6

Azitra's earnings are forecast to decline at 15% per annum while its annual revenue is expected to grow at 83.7% per year. EPS is expected to grow by 53.6% per annum.

Key information

-15.0%

Earnings growth rate

53.6%

EPS growth rate

Biotechs earnings growth	28.4%
Revenue growth rate	83.7%
Future return on equity	n/a
Analyst coverage	Low
Last updated	15 Nov 2024

Recent future growth updates

No updates

Recent updates

Earnings and Revenue Growth Forecasts

NYSEAM:AZTR - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	N/A	-16	N/A	N/A	2
12/31/2025	N/A	-13	N/A	N/A	2
12/31/2024	0	-10	N/A	N/A	2
9/30/2024	0	-9	-10	-10	N/A
6/30/2024	0	-10	-10	-9	N/A
3/31/2024	1	-12	-9	-9	N/A
12/31/2023	1	-13	-7	-7	N/A
9/30/2023	1	-15	-7	-7	N/A
6/30/2023	0	-16	-7	-7	N/A
3/31/2023	0	-14	-7	-7	N/A
12/31/2022	0	-13	-9	-8	N/A
9/30/2022	0	-13	-8	-8	N/A
12/31/2021	0	-12	-9	-8	N/A
12/31/2020	0	-7	-7	-7	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: AZTR is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: AZTR is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: AZTR is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: AZTR's revenue (83.7% per year) is forecast to grow faster than the US market (9% per year).

High Growth Revenue: AZTR's revenue (83.7% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if AZTR's Return on Equity is forecast to be high in 3 years time

Azitra Future Growth

Future criteria checks 2/6

Key information

Recent future growth updates

Recent updates

Third quarter 2024 earnings released: US$0.17 loss per share (vs US$4.82 loss in 3Q 2023)

Azitra, Inc., Annual General Meeting, Nov 20, 2024

Azitra, Inc Announces First Patient Dosed in Phase 1B Trial of ATR-12 for Netherton Syndrome

Azitra, Inc. Receives Study May Proceed Letter from the FDA for IND to Treat Skin Rash from EGFR Inhibitors

Azitra, Inc. Announces First Patient Screened and Scheduled to Enroll in Phase 1B Trial of ATR-12 for Netherton Syndrome

Second quarter 2024 earnings released: US$2.74 loss per share (vs US$70.87 loss in 2Q 2023)

New major risk - Revenue and earnings growth

Azitra, Inc. has completed a Follow-on Equity Offering in the amount of $9.9975 million.

First quarter 2024 earnings released: US$0.14 loss per share (vs US$3.00 loss in 1Q 2023)

Azitra, Inc. Announces Positive Preclinical Data of ATR-12 and Clinical Design in Netherton Syndrome Presented at the ASGCT Annual Meeting

Azitra, Inc. Announces New Preclinical Data to be Presented at the American Society of Gene and Cell Therapy Meeting

Full year 2023 earnings released: US$1.83 loss per share (vs US$12.74 loss in FY 2022)

New major risk - Market cap size

Azitra, Inc. has completed a Follow-on Equity Offering in the amount of $5.0001 million.

Azitra, Inc. has filed a Follow-on Equity Offering.

Third quarter 2023 earnings released: US$0.16 loss per share (vs US$2.95 loss in 3Q 2022)

Second quarter 2023 earnings released

Azitra Adds Barbara Ryan and John Schroer to Its Board of Directors

Azitra, Inc. Appoints Travis Whitfill as Chief Operating Officer

Azitra Inc has completed an IPO in the amount of $7.5 million.

Azitra Inc has completed an IPO in the amount of $7.5 million.

Less than half of directors are independent

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies